In ovarian cancer, currently, multiple TAAs, such as MUC16, EpCAM, CD47, NY-ESO-1, HER2, MSLN and FOLR1, have been utilized in CAR-T cell-based immunotherapy, but these approaches have failed to replicate the success of CD19 CAR-T cells in hematopoietic cancers. Here, EPCAM is linked to hematopoietic and lymphoid cell neoplasm.